ABSTRACT
ABSTRACT: In this report, we discuss contact lens (CL) fitting in a patient with a history of keratoconus (KC), before and after undergoing topography-guided photorefractive keratectomy (TG PRK). Before TG PRK, the patient failed multiple CL modalities and reported difficulty with his habitual CLs and inadequate spectacle-corrected visual acuity to perform his activities of daily living. In this case, a collaborative, comprehensive approach to visual management in a patient with KC was used, and after TG PRK was performed to improve his corneal contour and symmetry, our patient was fit with a standard soft CL and additionally had improved spectacle-corrected visual acuity.
Subject(s)
Contact Lenses, Hydrophilic , Keratoconus , Photorefractive Keratectomy , Humans , Photorefractive Keratectomy/adverse effects , Keratoconus/surgery , Activities of Daily Living , Lasers, Excimer/therapeutic use , Visual Acuity , Corneal Topography , Contact Lenses, Hydrophilic/adverse effects , Cross-Linking ReagentsABSTRACT
OBJECTIVE: To determine the effectiveness of netarsudil, 0.02% in lowering intraocular pressure (IOP) in patients with secondary forms of glaucoma. METHODS: A total of 77 patients (98 eyes) with either primary open-angle glaucoma (POAG) or secondary glaucoma were reviewed retrospectively over the course of 1 year after starting netarsudil. The secondary glaucoma group was comprised of patients with uveitic, pseudoexfoliative, neovascular, congenital, and other forms of secondary glaucoma. Patient IOP measurements were collected at baseline and at 1-, 3-, 6-, and 12-month intervals. Two sample t tests and 1-way analysis of variance were used to determine differences in IOP reductions following netarsudil treatment. RESULTS: Patients with POAG or secondary glaucomas were matched for age (mean ± SD: 69.1 ± 16.0 years vs. 64.5 ± 21.2 years; pâ¯=â¯0.30). Both the POAG and secondary glaucoma patients exhibited significant decreases in IOP at each time point (1, 3, 6, and 12 months) when compared with baseline (p < 0.05). Both groups showed similar overall decreases in IOP from baseline after 1 year of treatment (6.0 ± 4.5 mm Hg vs. 6.6 ± 8.4 mm Hg; pâ¯=â¯0.70). Forty-sex percent of POAG patients achieved an IOP of <14 mm Hg compared with 17% of secondary glaucoma patients. Among the secondary glaucoma subtypes, netarsudil was found to be most effective for treating uveitic glaucoma, showing a decrease in IOP of 9.5 mm Hg after 12 months (pâ¯=â¯0.02). CONCLUSION: Netarsudil is effective in lowering IOP in patients with certain forms of secondary glaucoma and should be considered for IOP management in those with uveitic glaucoma.
Subject(s)
Vision Disorders , Humans , Child , Vision Disorders/diagnosis , Vision Disorders/etiology , Visual AcuityABSTRACT
The use of netasurdil 0.02% (Rhopressa) in patients with primary open-angle glaucoma has been shown to be effective in lowering intraocular pressure (IOP). However, the effectiveness of netasurdil in patients with secondary forms of glaucoma has been minimally investigated. Previous reports have suggested its adequacy in lowering IOP in patients with congenital glaucoma. Its effectiveness in treating uveitic glaucoma, on the other hand, has yet to be formally examined. In a small group of patients with uveitic glaucoma, netasurdil has been shown to lower IOP by an average of 10.0mmHg, with over half of patients exhibiting more than a 20% decrease in IOP after 12 months of treatment. No patients developed any serious complications from taking netasurdil, however, conjunctival hyperemia was present in 15% of the patient population. Early success of netasurdil in patients with uveitic glaucoma warrants further investigation to better understand its safety and effectiveness.
